Clinical Trial TitleDART: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.
Clinical Trial Protocol Description:
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have histologically confirmed rare cancer and/or cancer of unknown primary, that did not have a match to a molecularly-guided therapy on EAY131 National Cancer Institute (NCI)-Molecular Analysis for Therapy Choice (MATCH) protocol or who progressed on molecularly-matched therapy and have no further molecularly-matched treatment recommendations per EAY131, NCI-MATCH.
- Have histologic documentation of metastatic malignancy with no discernible primary site identified from histopathologic review, physical exam and associated cross-sectional imaging of the chest, abdomen, and pelvis.
This is a partial list of elgibility requirements.